13F Holdings
中文EN

CDIO Cardio Diagnostics Holdings, Inc.

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1870144 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-3.8%
TTM net income YoY1.0%
TTM EPS YoY21.0%
Revenue 3-yr CAGR6.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-42,649.8%
Net margin-42,721.9%
FCF margin-38,090.8%
EBITDA margin-42,499.9%

Returns

ROE-93.5%
ROA-87.2%
ROIC (approx.)-136.2%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets6.0%
Debt / equity0.00x
Current ratio17.44x
Interest coverage-564.93x

Cash quality & payout

Operating cash flow / net income0.89x
Accruals ratio-9.5%
Payout ratio—
Capex / revenue11.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$3,590$5,360$2,680$3,555$2,855$7,475$940$4,512
R&D expense$174,250$162,929$129,776$286,867$189,049$178,536$118,784$5,758
SG&A expense$1.34M$1.14M$1.46M-$6,556$1.33M$1.30M$1.28M$41,241
Operating income-$1.73M-$1.50M-$1.78M-$1.46M-$1.71M-$1.68M-$1.63M-$1.52M
Interest expense$2,293$3,440$3,439$2,292$3,128$4,690$4,691$3,127
Pretax income-$1.73M-$1.50M-$1.79M-$1.47M-$1.71M-$1.68M-$1.64M-$1.52M
Net income-$1.73M-$1.50M-$1.79M-$1.47M-$1.71M-$1.68M-$1.64M-$1.52M
EBITDA-$1.72M-$1.49M-$1.78M-$1.46M-$1.71M-$1.67M-$1.59M-$1.57M
EPS (basic)-0.59-0.51-0.63—-0.98-0.97-0.97—
EPS (diluted)-0.59-0.51-0.63—-0.98-0.97-0.97—
Weighted avg. shares (diluted)2.96M2.96M2.84M—1.76M1.74M1.69M—
Balance sheet
Cash & equivalents$0$0$0$0$6.36M$7.97M$9.69M$7.83M
Receivables$3,550$3,905$4,274$8,126$11,221$12,927$9,552$18,612
Current assets$4.35M$6.16M$7.74M$5.92M$6.93M$8.70M$10.54M$8.79M
PP&E, net$569,070$613,352$657,635$700,115$744,335$621,903$640,992$672,861
Intangibles——————$1,333$5,333
Total assets$6.08M$7.93M$9.56M$7.77M$8.79M$10.40M$12.28M$10.62M
Current liabilities$249,619$359,197$491,443$604,839$398,448$369,597$540,616$631,695
Total liabilities$366,002$499,780$655,972$793,061$637,331$671,848$904,998$1.06M
Shareholders' equity$5.72M$7.43M$8.90M$6.97M$8.15M$9.72M$11.38M$9.56M
Shares outstanding2.96M2.96M2.96M1.83M1.77M1.74M1.74M1.53M
Cash flow statement
Operating cash flow-$1.52M-$1.34M-$1.56M-$1.36M-$1.39M-$1.57M-$1.40M-$1.39M
Capital expenditure$0$0$1,760$0$162,834$18,696$5,787$3,638
Free cash flow-$1.52M-$1.34M-$1.56M-$1.36M-$1.56M-$1.59M-$1.41M-$1.40M
Investing cash flow-$60,469-$46,789-$63,696-$78,359-$257,819-$35,717-$47,415-$54,613
Financing cash flow-$67,448-$101,171$3.59M$195,620$39,955-$115,037$3.31M$7.29M
Depreciation & amortization$5,979$5,593$5,532$5,655$5,655$8,485$45,438-$56,603
Stock-based compensation$24,338$24,352$24,733$24,083$24,762$30,778$30,612$22,415

Free plan shows the latest 8 periods; Pro shows all 20 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.